Clinical Edge Journal Scan

Opioid use more frequent in patients with chronic migraine


 

Key clinical point: Use of opioids is still prevalent among patients with migraine, thus indicating non-adherence to evidence-based international guidelines; moreover, the opioid use is more frequent and prolonged among patients with chronic migraine (CM) than among those with episodic migraine (EM).

Major finding: Overall, 13.4% of patients reported ever using an opioid for headache, with 46.3% using opioids occasionally, whereas 27.0% and 11.3% reported using them for >1 month and >1 year, respectively. Additionally, 2.4% of participants used opioids without a prescription. Patients with CM vs EM reported more frequent (21.6% vs 11.7%; P < .001) and prolonged (>1 month: 33.6% vs 24.4%; P < .003; >1 year: 17.7% vs 8.7%; P < .001) opioid use.

Study details: Findings are from a cross-sectional questionnaire-based study including 3712 patients with migraine (CM n = 629; EM n = 3,083).

Disclosures: This study did not receive any funding. GM Terwindt declared receiving consultancy support and independent support from various sources. No other conflicts of interest were declared.

Source: van Welie RF, van Welie FC, et al. Characterizing opioid use in a Dutch cohort with migraine. Cephalalgia. 2023;43(5) (May 11). doi: 10.1177/03331024231174160

Recommended Reading

Update on Migraine Prevention 2023
Migraine ICYMI
Maternal migraine raises risk for childhood cancers in offspring
Migraine ICYMI
Omega-3 supplementation may improve inflammatory markers in episodic migraine
Migraine ICYMI
Commentary: CGRP medications, COVID-19, and menopause in patients with migraine, June 2023
Migraine ICYMI
New diagnostic criteria for menstrual migraine
Migraine ICYMI
Concomitant oral preventive treatment may dampen response in chronic migraine treated with onabotulinumtoxinA
Migraine ICYMI
Efficacy of galcanezumab after 1 week of treatment for migraine predicts responders at 3 months
Migraine ICYMI
Perimenstrual migraine attacks are exclusively migraine attacks without aura, recommends study
Migraine ICYMI
Real-world data show benefits of anti-CGRP mAb in migraine patients age ≥ 65 years
Migraine ICYMI
Fremanezumab switch may benefit migraine patients who are not responding to anti-CGRP mAb
Migraine ICYMI